Outi Leppäranta

1.2k total citations
16 papers, 940 citations indexed

About

Outi Leppäranta is a scholar working on Pulmonary and Respiratory Medicine, Orthodontics and Biomedical Engineering. According to data from OpenAlex, Outi Leppäranta has authored 16 papers receiving a total of 940 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Orthodontics and 5 papers in Biomedical Engineering. Recurrent topics in Outi Leppäranta's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers), Medical Imaging and Pathology Studies (6 papers) and Bone Tissue Engineering Materials (5 papers). Outi Leppäranta is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers), Medical Imaging and Pathology Studies (6 papers) and Bone Tissue Engineering Materials (5 papers). Outi Leppäranta collaborates with scholars based in Finland, United States and Sweden. Outi Leppäranta's co-authors include Matti K. Viljanen, Heimo O. Ylänen, Leena Hupa, Eveliina Munukka, Erkki Eerola, Mikko Hupa, Minna Vaahtio, Timo Peltola, Jukka I. Salonen and Marjukka Myllärniemi and has published in prestigious journals such as Journal of Cellular Physiology, Journal of Histochemistry & Cytochemistry and Cell and Tissue Research.

In The Last Decade

Outi Leppäranta

16 papers receiving 919 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Outi Leppäranta Finland 12 499 309 306 217 153 16 940
Uk‐Kyu Kim South Korea 18 250 0.5× 287 0.9× 246 0.8× 112 0.5× 72 0.5× 96 1.1k
Franz Josef Strauß Switzerland 23 262 0.5× 713 2.3× 207 0.7× 174 0.8× 132 0.9× 106 1.7k
Tetuo Okamoto Brazil 19 268 0.5× 346 1.1× 158 0.5× 62 0.3× 112 0.7× 61 933
Go Ohe Japan 20 237 0.5× 210 0.7× 142 0.5× 82 0.4× 49 0.3× 37 884
Shinji Iyama Japan 16 193 0.4× 209 0.7× 176 0.6× 59 0.3× 117 0.8× 34 841
Toshiyuki Kawakami Japan 16 147 0.3× 409 1.3× 148 0.5× 65 0.3× 86 0.6× 129 1.0k
Cláudia Cristina Biguetti Brazil 18 184 0.4× 295 1.0× 139 0.5× 60 0.3× 28 0.2× 61 993
Mia Rakić Serbia 17 181 0.4× 715 2.3× 136 0.4× 285 1.3× 46 0.3× 49 1.1k
Ming‐Gene Tu Taiwan 20 323 0.6× 831 2.7× 214 0.7× 326 1.5× 19 0.1× 46 1.4k

Countries citing papers authored by Outi Leppäranta

Since Specialization
Citations

This map shows the geographic impact of Outi Leppäranta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Outi Leppäranta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Outi Leppäranta more than expected).

Fields of papers citing papers by Outi Leppäranta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Outi Leppäranta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Outi Leppäranta. The network helps show where Outi Leppäranta may publish in the future.

Co-authorship network of co-authors of Outi Leppäranta

This figure shows the co-authorship network connecting the top 25 collaborators of Outi Leppäranta. A scholar is included among the top collaborators of Outi Leppäranta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Outi Leppäranta. Outi Leppäranta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
2.
Myllärniemi, Marjukka, Jussi Tikkanen, Juha J. Hulmi, et al.. (2014). Upregulation of activin-B and follistatin in pulmonary fibrosis – a translational study using human biopsies and a specific inhibitor in mouse fibrosis models. BMC Pulmonary Medicine. 14(1). 170–170. 17 indexed citations
3.
Rönty, Mikko, Alexander P. Wohl, Sakari Joenväärä, et al.. (2013). Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis. 2(8). e66–e66. 36 indexed citations
4.
Leppäranta, Outi, Jussi Tikkanen, Maxim M. Bespalov, Katri Koli, & Marjukka Myllärniemi. (2012). Bone Morphogenetic Protein–Inducer Tilorone Identified by High-Throughput Screening Is Antifibrotic In Vivo. American Journal of Respiratory Cell and Molecular Biology. 48(4). 448–455. 27 indexed citations
5.
Leppäranta, Outi, Carla Sens, Kaisa Salmenkivi, et al.. (2012). Regulation of TGF-β storage and activation in the human idiopathic pulmonary fibrosis lung. Cell and Tissue Research. 348(3). 491–503. 58 indexed citations
6.
Järvinen, Päivi M., Marjukka Myllärniemi, Hester Liu, et al.. (2011). Cysteine‐rich protein 1 is regulated by transforming growth factor‐β1 and expressed in lung fibrosis. Journal of Cellular Physiology. 227(6). 2605–2612. 12 indexed citations
7.
Zhang, Di, Outi Leppäranta, Eveliina Munukka, et al.. (2009). Antibacterial effects and dissolution behavior of six bioactive glasses. Journal of Biomedical Materials Research Part A. 93A(2). 475–483. 231 indexed citations
8.
Leppäranta, Outi, Marjukka Myllärniemi, Kaisa Salmenkivi, et al.. (2009). Reduced Phosphorylation of the TGF-β Signal Transducer Smad2 in Emphysematous Human Lung. COPD Journal of Chronic Obstructive Pulmonary Disease. 6(4). 234–241. 8 indexed citations
9.
Leppäranta, Outi, Ville Pulkkinen, Katri Koli, et al.. (2009). Transcription Factor GATA-6 Is Expressed in Quiescent Myofibroblasts in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 42(5). 626–632. 42 indexed citations
10.
Palmu, Kaisa, et al.. (2008). Characterization of the Alnumycin Gene Cluster Reveals Unusual Gene Products for Pyran Ring Formation and Dioxan Biosynthesis. Chemistry & Biology. 15(10). 1046–1057. 51 indexed citations
11.
Vuorinen, Kirsi, Steffen Ohlmeier, Outi Leppäranta, et al.. (2008). Peroxiredoxin II Expression and Its Association With Oxidative Stress and Cell Proliferation in Human Idiopathic Pulmonary Fibrosis. Journal of Histochemistry & Cytochemistry. 56(10). 951–959. 37 indexed citations
12.
Hartiala, Pauliina, et al.. (2007). Borrelia burgdorferi inhibits human neutrophil functions. Microbes and Infection. 10(1). 60–68. 24 indexed citations
13.
Munukka, Eveliina, Outi Leppäranta, Mika Korkeamäki, et al.. (2007). Bactericidal effects of bioactive glasses on clinically important aerobic bacteria. Journal of Materials Science Materials in Medicine. 19(1). 27–32. 209 indexed citations
14.
Leppäranta, Outi, Minna Vaahtio, Timo Peltola, et al.. (2007). Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro. Journal of Materials Science Materials in Medicine. 19(2). 547–551. 163 indexed citations
15.
Zhang, Di, Eveliina Munukka, Outi Leppäranta, et al.. (2006). Comparison of Antibacterial Effect of Three Bioactive Glasses. Key engineering materials. 309-311. 345–348. 10 indexed citations
16.
Vaahtio, Minna, Eveliina Munukka, Outi Leppäranta, et al.. (2006). Effect of Ion Release on Antibacterial Activity of Melt-Derived and Sol-Gel-Derived Reactive Ceramics. Key engineering materials. 309-311. 349–354. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026